Sobi Ramps Up In Rare Diseases With Apellis Deal
$250m Upfront Fee For Rights To Pegcetacoplan
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
You may also be interested in...
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.
Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.